Marina Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 23-12-2024
- Paid Up Capital ₹ 0.84 M
as on 23-12-2024
- Company Age 17 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
as on 23-12-2024
- Satisfied Charges ₹ 3.00 M
as on 23-12-2024
- Revenue -6.53%
(FY 2020)
- Profit 79.69%
(FY 2020)
- Ebitda 196.15%
(FY 2020)
- Net Worth -3.81%
(FY 2020)
- Total Assets 4.15%
(FY 2020)
About Marina Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 0.84 M.
The company currently has active open charges totaling ₹2.00 M. The company has closed loans amounting to ₹3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Prince Kumar, Mrigank Goyal, and Rina Kumari serve as directors at the Company.
- CIN/LLPIN
U85110BR2007PTC012933
- Company No.
012933
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Apr 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Marina Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prince Kumar  | Director | 27-Apr-2007 | Current |
| Mrigank Goyal | Whole-Time Director | 01-Apr-2020 | Current |
| Rina Kumari | Director | 27-Apr-2007 | Current |
Financial Performance of Marina Pharmaceuticals.
Marina Pharmaceuticals Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 6.53% decrease. The company also saw a substantial improvement in profitability, with a 79.69% increase in profit. The company's net worth dipped by a decrease of 3.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Marina Pharmaceuticals?
In 2020, Marina Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Florid Laboratories Private LimitedActive 5 years 8 months
Prince Kumar, Mrigank Goyal and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Icici Banklimited Creation Date: 24 Dec 2015 | ₹2.00 M | Open |
Others Creation Date: 14 Feb 2017 | ₹3.00 M | Satisfied |
How Many Employees Work at Marina Pharmaceuticals?
Unlock and access historical data on people associated with Marina Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Marina Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Marina Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
